Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02691923 · ClinicalTrials.gov registry record · Phase 2
Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker
A Phase 2 study of Brain Cancer, sponsored by David W. Roberts.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT02691923: Recruiting Phase 2 study of Brain Cancer, sponsored by David W. Roberts.
NCT02691923 is a Phase 2 study of Brain Cancer that is actively recruiting participants, run by David W. Roberts. The registered enrollment target is 30 participants, below the 507-participant average among 47 other Brain Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02691923, a Phase 2 study of Brain Cancer, is actively recruiting participants, sponsored by David W. Roberts.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical research will evaluate the diagnostic potential of fluorescein as visualized through an operating microscope relative to 1) contrast enhancement on co-registered preoperative MR scans, 2) intraoperative ALA-induced PpIX fluorescence and 3) gold-standard histology obtained from biopsy sampling during the procedure. Subjects will include those people with operable brain tumor with first-time presumed pre-surgical diagnosis of high-grade glioma or low-grade glioma.
Primary Outcome
The predictive performance of fluorescein fluorescence as an intraoperative imaging biomarker of tumor during surgery in patients with a clinical diagnosis of high grade glioma (HGG) and patients with a clinical diagnosis of low grade glioma (LGG) will be measured. Fluorescence will be measured both quantitatively via an intraoperative probe and visually by the neurosurgeon through the operating microscope. Endpoints will be assessed separately for HGG and LGG groups.
Conditions Studied
Interventions
- DRUG Fluorescein
- DRUG Fluorescein + ALA
Study Locations (1)
New Hampshire
- Sally B Mansur - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-03 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What NCT02691923 shows while recruiting
NCT02691923 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 507-participant average among 47 other Brain Cancer trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Brain Cancer appearing as the primary indexed condition, and to 2 interventions - of which Fluorescein is the first listed.
NCT02691923 reports a single indexed study location in New Hampshire.
Frequently Asked Questions
What is clinical trial NCT02691923 about?
NCT02691923 is a clinical study titled "Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker". This clinical research will evaluate the diagnostic potential of fluorescein as visualized through an operating microscope relative to 1) contrast enhancement on co-registered preoperative MR scans, 2) intraoperative ALA-induced PpIX fluorescence and 3) gold-standard histology obtained from biopsy s...
What is the current status of trial NCT02691923?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2016-03. Estimated completion is 2026-12.
What conditions does trial NCT02691923 study?
This clinical trial studies the following conditions: Brain Cancer.
What interventions are being tested in trial NCT02691923?
The interventions under investigation include: Fluorescein (DRUG), Fluorescein + ALA (DRUG).
Who is sponsoring clinical trial NCT02691923?
This trial is sponsored by David W. Roberts, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02691923 being conducted?
This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02691923's enrollment target sits among peer trials
30 32nd of 47 higher than 14 of 47 other Brain Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
RECRUITING · Phase 2
-
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
RECRUITING · Phase 2
-
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
RECRUITING · Phase 2
-
Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis
RECRUITING · Phase 2
-
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
RECRUITING · Phase 2
-
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia